John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

An algorithm for the management of hepatic dysfunction in hematology Volume 26, issue 2, Février 2019

  • [1] Gratwohl A., Pasquini M.C., Aljurf M. One million haemopoietic stem-cell transplants : a retrospective observational study. Lancet Haematol. 2015;2:e91-100. 3
  • [2] Devine S.M., Owzar K., Blum W. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen : Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015;33:4167-4175. 35
  • [3] Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med 2017 ; 376 (9) : 848-55.
  • [4] Thompson A.A., Walters M.C., Kwiatkowski J. Gene Therapy in Patients with Transfusion-Dependent beta-Thalassemia. N Engl J Med. 2018;378:1479-1493. 16
  • [5] Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation : a study of 193 patients. Blood 2004 ; 103 (1) : 78-84.
  • [6] Locasciulli A., Alberti A., de Bock R. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe : a survey from the European Bone Marrow Transplantation (EBMT) Group--Infectious Diseases Working Party. Bone Marrow Transplant. 1994;14:833-837. 5
  • [7] Gooley TA, Rajvanshi P, Schoch HG, et al. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology 2005 ; 41 (2) : 345-52.
  • [8] Chalasani N.P., Hayashi P.H., Bonkovsky H.L. ACG Clinical Guideline : the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950-966. 7
  • [9] Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation : a cohort study with 10-year follow-up. Hepatology 1999 ; 29 (6) : 1893-9.
  • [10] Torres H.A., Shigle T.L., Hammoudi N. The oncologic burden of hepatitis C virus infection : A clinical perspective. CA Cancer J Clin. 2017;67:411-431. 5
  • [11] Eddleston M., Peacock S., Juniper M. Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis. 1997;24:52-56. 1
  • [12] Grant R.M., Weitzman S.S., Sherman C.G. Fulminant disseminated Varicella Zoster virus infection without skin involvement. J Clin Virol. 2002;24:7-12. 1–2
  • [13] Palanduz A., Yildirmak Y., Telhan L. Fulminant hepatic failure and autoimmune hemolytic anemia associated with Epstein-Barr virus infection. J Infect. 2002;45:96-98. 2
  • [14] Neofytos D., Ojha A., Mookerjee B. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant. 2007;13:74-81. 1
  • [15] Inazawa N., Hori T., Nojima M. Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay. J Med Virol. 2017;89:358-362. 2
  • [16] McDonald GB, Freston JW, Boyer JL, et al. Liver complications following treatment of hematologic malignancy with anti-cd22-calicheamicin (Inotuzumab Ozogamicin). Hepatology. 2018. Aug 18. doi: 10.1002/hep.30222.[Epub ahead of print].
  • [17] McKoy J.M., Angelotta C., Bennett C.L. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS) : an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31:599-604. 5
  • [18] Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004 ; 15 (3) : 460-6.
  • [19] Malik A.H., Collins R.H. Jr., Saboorian M.H. Chronic graft-versus-host disease after hematopoietic cell transplantation presenting as an acute hepatitis. Am J Gastroenterol. 2001;96:588-590. 2
  • [20] Strasser S.I., Shulman H.M., Flowers M.E. Chronic graft-versus-host disease of the liver: Presentation as an acute hepatitis. Hepatology. 2000;32:1265-1271. 6
  • [21] Laemmle A., Hahn D., Hu L.Y. Fatal hyperammonemia and carbamoyl phosphate synthetase 1 (CPS1) deficiency following high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Mol Genet Metab. 2015;114:438-444. 3
  • [22] Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology 2007 ; 45 (1) : 230-41.
  • [23] Scharte M., Fink M.P. Red blood cell physiology in critical illness. Crit Care Med. 2003;31:S651-S657. 12 Suppl.
  • [24] Gooley T.A., Chien J.W., Pergam S.A. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091-2101. 22
  • [25] Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002 ; 100 (6) : 1977-83.
  • [26] Shulman H.M., Sharma P., Amos D. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology. 1988;8:463-470. 3
  • [27] Ogose T., Watanabe T., Suzuya H. Autoimmune hepatitis following allogeneic PBSCT from an HLA-matched sibling. Bone Marrow Transplant. 2003;31:829-832. 9
  • [28] McDonald G.B., Slattery J.T., Bouvier M.E. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101:2043-2048. 5
  • [29] Parlati L., Vallet-Pichard A., Batista R. Incidence of grade 3-4 liver injury under immune checkpoints inhibitors : A retrospective study. J Hepatol. 2018;69:1396-1397. 6
  • [30] Bjornsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481-489. 2
  • [31] Hubscher S.G., Lumley M.A., Elias E. Vanishing bile duct syndrome: A possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology. 1993;17:70-77. 1
  • [32] Maertens J., Marchetti O., Herbrecht R. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL 3--2009 update. Bone Marrow Transplant. 2011;46:709-718. 5
  • [33] Yasmineh W.G., Killeen A.A., Filipovich A.H. Conjugated hyperbilirubinemia and renal function in bone marrow transplant recipients. Arch Pathol Lab Med. 1988;112:245-250. 3
  • [34] Grier J.F., Cohen S.W., Grafton W.D. Acute suppurative cholangitis associated with choledochal sludge. Am J Gastroenterol. 1994;89:617-619. 4
  • [35] Darwish Murad S., Plessier A., Hernandez-Guerra M. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151:167-175. 3
  • [36] Dentali F., Squizzato A., Brivio L. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: A meta-analysis. Blood. 2009;113:5617-5623. 22
  • [37] Smalberg J.H., Arends L.R., Valla D.C. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: A meta-analysis. Blood. 2012;120:4921-4928. 25
  • [38] Hill A., Kelly R.J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985-96. 25
  • [39] DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids : sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002 ; 22 (1) : 27-42.
  • [40] McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993 ; 118 (4) : 255-67.
  • [41] McCune J.S., Batchelder A., Guthrie K.A. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen : a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther. 2009;85:615-622. 6
  • [42] Jenke A., Freiberg-Richter J., Wilhelm S. Accidental busulfan overdose during conditioning for stem cell transplantation. Bone Marrow Transplant. 2005;35:125-128. 2
  • [43] Rezvani A.R., McCune J.S., Storer B.E. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: Pharmacokinetics and clinical outcomes. Biol Blood Marrow Transplant. 2013;19:1033-1039. 7
  • [44] van Iersel L.B., de Leede E.M., Vahrmeijer A.L. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. Eur J Surg Oncol. 2014;40:1557-1563. 11
  • [45] Abbasi N., Vadnais B., Knutson J.A. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol. 2011;51:1429-1438. 10
  • [46] Godwin CD, McDonald GB, Walter RB. Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood 2017 ; 129 (16) : 2330-2.
  • [47] Wadleigh M., Richardson P.G., Zahrieh D. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578-1582. 5
  • [48] Mallet V, van Bommel F, Doerig C, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation : recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 2016 ; 16 (5) : 606-17.
  • [49] Rossetti F., Brawner D.L., Bowden R. Fungal liver infection in marrow transplant recipients : prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis. 1995;20:801-811. 4
  • [50] Marchetti O., Lamoth F., Mikulska M. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47:846-854. 6
  • [51] Barba P., Pinana J.L., Fernandez-Aviles F. Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: A study of 455 patients. Biol Blood Marrow Transplant. 2011;17:1653-1661. 11
  • [52] de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop : Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743-752. 3
  • [53] Wermke M., Schmidt A., Middeke J.M. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin Cancer Res. 2012;18:6460-6468. 23
  • [54] McDonald G.B., Evans A.T., McCune J.S. Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: A retrospective cohort study. The Lancet Haematology. 2016;3:e516-e525. 11
  • [55] Torres H.A., McDonald G.B. How I treat hepatitis C virus infection in patients with hematologic malignancies. Blood. 2016;128:1449-1457. 11
  • [56] McDonald G.B. How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. Blood. 2016;127:1544-1550. 12
  • [57] McDonald G.B. Hepatobiliary Complications of Hematopoietic Cell Transplantation, 40 Years On. Hepatology. 2010;51:1450-1460. 4
  • [58] Kida A., McDonald G.B. Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation. Semin Hematol. 2012;49:43-58. 1